Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Newly Diagnosed Multiple Myeloma
NCT03012880Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2017
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib, daratumumab in multiple myeloma (MM), sponsored by Mayo Clinic. Started Apr 2017; status: completed.
02
Drugs
ixazomibdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03012880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012880.